About a fourth of younger men surveyed in the United States feel lonely, which is significantly higher than the national ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Results showed that replacing a half-hour of sedentary time with a half-hour of moderate-to-vigorous physical activity every ...

CALIFORNIA, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- The Type 2 Diabetes market is undergoing significant ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Key Takeaways Novo Nordisk is teaming up with U.S. biotech Septerna to create a new obesity pillSepterna could receive up to ...

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering ...

Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...